Yahoo Web Search

Search results

1. • Monitoring Abbvie Inc (ABBV) after recent insider movements – Knox Daily

     Knox Daily· 1 day ago

     Abbvie Inc’s filing revealed that its EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas unloaded Company’s shares for reported $3.72 million on Mar 20 ’24.

2. • AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts

     ETF DAILY NEWS· 5 days ago

     AbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued ...

3. • Abbvie Inc (NYSE: ABBV) Jumps 1.36%: What Could Be On The Way Going Forward? – Stocks Register

     Stocks Register· 5 days ago

     Abbvie Inc (NYSE:ABBV) shares, rose in value on Wednesday, May 15, with the stock price up by 1.36% to the previous day’s close as strong demand from buyers ...

4. • 

     Unlocking Intrinsic Value: Analysis of AbbVie Inc

     GuruFocus.com via Yahoo Finance· 7 days ago

     In this article, we will take a look into AbbVie Inc's (NYSE:ABBV) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value.

5. • ABBV Stock Sees Surge of Approximately 2.08% in Last Five Days – Knox Daily

     Knox Daily· 5 days ago

     Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Abbvie Inc shares valued at $3,716,757 were sold by ...

6. • 

     AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal

     Zacks via Yahoo Finance· 7 days ago

     AbbVie Inc. ABBV announced that it has signed a collaboration and option-to-license agreement with...

7. • 

     Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

     Zacks via Yahoo Finance· 7 days ago

     AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good...

8. • 

     AbbVie shares hold Buy rating with $180 target from TD Cowen By Investing.com

     Investing.com· 7 days ago

     On Tuesday, TD (TSX:TD) Cowen maintained a positive stance on AbbVie Inc . TD Cowen adjusted its...

9. • 

     AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst - AbbVie...

     Benzinga· 4 days ago

     Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target....

10. • Maryland Drug Board Advances Ozempic, Other Cost Reviews (1)

      Bloomberg Law· 13 hours ago

      Blockbuster diabetes drugs Ozempic and Trulicity will be included in the Maryland prescription drug board’s first cost review, a monthslong process that will help the panel determine whether ...